Search

Displaying results 3391 - 3400 of 4599 in total
  1. Drug

    Doramectin

    go.drugbank.com/drugs/DB11400
    ExperimentalVet approved

    Doramectin is a veterinary drug approved by the Food and Drug Administration for the treatment of parasites such as gastrointestinal roundworms, lungworms, eyeworms, grubs, sucking lice and mange mites

  2. Drug

    WP-1301

    go.drugbank.com/drugs/DB17702
    Experimental

    It binds to an MHC class II molecule and is recognized by a Factor VIII-specific T cell.[L46138]

  3. Drug

    AGA2115

    go.drugbank.com/drugs/DB17840
    Investigational

    Developed by Angitia Biopharmaceuticals, AGA2115 is being investigated for the treatment of osteogenesis imperfect.[L46646]

  4. Drug

    Agatolimod

    go.drugbank.com/drugs/DB15018
    Investigational

    Agatolimod is under investigation in clinical trial NCT00471471 (Vaccine Therapy in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery).

  5. Drug

    XT-150

    go.drugbank.com/drugs/DB21756
    Investigational

    [L52125] It is being developed by Xalud Therapeutics.

  6. Drug

    Methdilazine

    go.drugbank.com/drugs/DB00902
    Approved

    Methdilazine is a phenothiazine compound with antihistaminic activity. It is used in the treatment of various dermatoses to relieve pruritus.

  7. Drug

    Lumiliximab

    go.drugbank.com/drugs/DB06162
    Investigational

    Lumiliximab was developed by IDEC Pharmaceuticals, which was acquired by Biogen. Clinical trials for CLL were terminated in 2010, and for allergic asthma in 2007.

  8. Drug

    Dirlotapide

    go.drugbank.com/drugs/DB11399
    InvestigationalVet approved

    It is marketed by Pfizer and Zoetis under the brand name, _Slentrol_, and is not intended for human use.

  9. Drug

    Metampicillin

    go.drugbank.com/drugs/DB13836
    Experimental

    Metampicillin is a penicillin antibiotic prepared by the reaction of ampicillin with formaldehyde. It is hydrolysed in aqueous solution to form ampicillin.

  10. Drug

    Luspatercept

    go.drugbank.com/drugs/DB12281
    ApprovedInvestigational

    Luspatercept is a recombinant fusion protein comprised of a modified extracellular domain of activin receptor type IIB fused to the FC domain of human IgG1. It was first approved for use in the United States in November 2019 under the br...